Clinical Trial Update: Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial evaluating UCAR-T cells targeting CD19 and BCMA for refractory idiopathic membranous nephropathy; the study status is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Membranous Nephropathy

Drugs mentioned

• UCAR-T (Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells) (anti-CD19/BCMA universal CAR-T cells)

Snippet

Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University | Conditions: Refractory Idiopathic Membranous Nephropathy | EARLY_Phase 1 | Status: NOT_YET_RECRUITING